London, UK, October 3, 2014 - PAREXEL International Corporation (Nasdaq: PRXL)("PAREXEL" or the "Company"), a global clinical research organisation, announced today that the Company has acquired all of the outstanding equity securities of privately-owned ClinIntel, a provider of clinical Randomisation and Trial Supply Management (RTSM) services, based in the United Kingdom.

ClinIntel's offerings will be combined into the ClinPhone® RTSM suite and are designed to make patient randomisation and clinical supply chain solutions more efficient.  Capabilities include advanced RTSM technologies for planning, forecasting and supply chain eLogistics. The offerings are particularly helpful in accelerating study start-up timelines.  The entire ClinPhone® RTSM suite will be available through the Perceptive MyTrials® platform and as a standalone solution, and both solutions will be available through the Perceptive® Partner Program.

ClinIntel was founded in 2009, and works with biopharmaceutical companies and contract research organisations. The company is headquartered in Crawley, United Kingdom. The acquisition was funded with existing cash, and the impact of the acquisition on PAREXEL's Fiscal Year 2015 revenue and earnings per share is not expected to be material. The business will be integrated into the PAREXEL Informatics segment.

Josef von Rickenbach, Chairman and CEO of PAREXEL International stated, "As the use of technology has expanded in the conduct of clinical research, PAREXEL has been a leader in Randomisation and Trial Supply Management.  By combining the trial supply management technologies from ClinIntel with our existing ClinPhone solutions, we believe we have an opportunity to further advance our position as a clinical technology leader and grow market share by bringing enhanced speed, efficiency, and simplicity to our RTSM offering."